Patents by Inventor Beibei Chen

Beibei Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200405715
    Abstract: The present disclosure is directed to, e.g., 3-substituted, 5-amine-substituted-cyclohex-2-en-1-one compounds, and method of treatment and making associated with the same compounds.
    Type: Application
    Filed: February 24, 2017
    Publication date: December 31, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Beibei Chen, Yuan Liu
  • Patent number: 10869866
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: December 22, 2020
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20200216426
    Abstract: A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy; R8 is an optionally-substituted heterocycloalkyl; and a is 0 to 3.
    Type: Application
    Filed: June 25, 2018
    Publication date: July 9, 2020
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Rama K. Mallampalli, Beibei Chen, Charleen T. Chu, Yuan Liu
  • Publication number: 20200113900
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Application
    Filed: June 18, 2019
    Publication date: April 16, 2020
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20200087294
    Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.
    Type: Application
    Filed: October 11, 2019
    Publication date: March 19, 2020
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20200062693
    Abstract: Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
    Type: Application
    Filed: October 4, 2017
    Publication date: February 27, 2020
    Inventors: Beibei CHEN, Rama K. MALLAMPALLI, Yuan LIU
  • Publication number: 20190367462
    Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Beibei CHEN
  • Patent number: 10487076
    Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 26, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government, as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10369150
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 6, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10344003
    Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: July 9, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Beibei Chen
  • Patent number: 10307423
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: June 4, 2019
    Assignees: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20190091222
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Application
    Filed: October 10, 2018
    Publication date: March 28, 2019
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10159674
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 25, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10092526
    Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, C3-7heterocycloalkyl, C3-7heterocycloalkyl-C1-6alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: October 9, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama Mallampalli
  • Publication number: 20180141916
    Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.
    Type: Application
    Filed: April 21, 2016
    Publication date: May 24, 2018
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Beibei CHEN
  • Publication number: 20180134693
    Abstract: A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.
    Type: Application
    Filed: December 10, 2015
    Publication date: May 17, 2018
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Publication number: 20180071232
    Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, C3-7heterocycloalkyl, C3-7heterocycloalkyl-C1-6alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
    Type: Application
    Filed: November 17, 2017
    Publication date: March 15, 2018
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama Mallampalli
  • Patent number: 9849098
    Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 26, 2017
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama Mallampalli
  • Patent number: 9765573
    Abstract: A composite tungsten carbide insert (B, I) with heterogeneous composition and structure has a working part (W) and a non-working part (N). The working part (W) is made of a tungsten carbide material consisting of tungsten carbide powder and cobalt powder or nickel. The non-working part (N) is made of a low density tungsten carbide material consisting of titanium carbide powder, tungsten carbide powder, and cobalt powder or nickel powder. During pressing, the tungsten carbide material for the working part (W) and the low density tungsten carbide material for the non-working part (N) are weighed and added to a steel die successively for molding and then sintering. The non-working part (N) which accounts for most of the overall product volume has low density and less material consumption, and can greatly reduce the raw material costs of the product, significantly improving the performance-cost ratio of the insert (B, I).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 19, 2017
    Assignee: Shanghai Gogoal Industry Co., Ltd.
    Inventors: Dacheng Luo, Shun Lin, Beibei Chen
  • Publication number: 20170014912
    Abstract: A composite tungsten carbide insert (B, I) with heterogeneous composition and structure has a working part (W) and a non-working part (N). The working part (W) is made of a tungsten carbide material consisting of tungsten carbide powder and cobalt powder or nickel. The non-working part (N) is made of a low density tungsten carbide material consisting of titanium carbide powder, tungsten carbide powder, and cobalt powder or nickel powder. During pressing, the tungsten carbide material for the working part (W) and the low density tungsten carbide material for the non-working part (N) are weighed and added to a steel die successively for molding and then sintering. The non-working part (N) which accounts for most of the overall product volume has low density and less material consumption, and can greatly reduce the raw material costs of the product, significantly improving the performance-cost ratio of the insert (B, I).
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: Shanghai Gogoal Industry Co., Ltd
    Inventors: Dacheng Luo, Shun Lin, Beibei Chen